Skip to main content
ARCT $7.45 -1.97%
ARCT logo
ARCT · Arcturus Therapeutics Holdings Inc.
Track ARCT — free
$7.45 -0.15 (-1.97%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$214.73M
Shares
28.82M
Volume · Nov 20 602K Avg daily vol (3M) 883.08K
All webcasts

Conference · 2026-09-09

Arcturus Therapeutics Holdings Inc. (ARCT) September 9, 2026 Conference Transcript

Concluded Sep 9, 2026 Audio replay Verified speakers
Sep 9, 2026 37:08 39 turns
Period
2026-09-09
Runtime
37:08
Sources
2 artifacts

Transcript & audio

Verified speakers 37:08 Audio
Miguel Nachamavitz Analyst — Citi

Day one of the Back to School Biopharma Conference City is hosting here in New York. I'm Miguel Nachamavitz, a biotech analyst. We're on our third session of the morning, which is my great pleasure to introduce Arcturus Therapeutics. We have both the CEO, Joe Payne, and Alan is the CMO, new CMO, relatively new CMO. So welcome, both of you. Appreciate it. Thank you. It's good to be with you. Um, so Joe, um, lots happened in the last, you know, a couple of years with the company, um, both on the, um, OCT front and then also on the, uh, CF front. So it'd be great if we could, you know, just start with the high level, uh, kind of introduce the company, uh, what are the key programs? Um, and, uh, we'll have plenty to talk about on both those programs.

Speaker 2

So, uh, Arcturus is a messenger RNA, a messenger RNA medicines company. that we have next generation technologies that differentiate us from the field and within the mRNA community. We do have a self-amplifying mRNA technology to support the vaccines division, but we utilize the self-amplifying mRNA platform, which includes infectious disease vaccines and potential cancer applications. We utilize that division to fund, non-dilutively fund, the value-creating portion of the organization, and that's our therapeutics pipeline. We have a pair of messenger RNA therapeutics that are deep in phase two with some meaningful milestones and readouts this year. So our liver platform has a flagship asset that's for an indication called ornithine transcarbamylase deficiency or OTC deficiency. it's the number one urea cycle disorder and we have a phase two readout for that later this month so it's a very near-term milestone for us and along with some regulatory clarity associated with that program that flagship program for the liver the liver platform and then we also have an inhaled messenger rna platform that's led by a cf product or cystic fibrosis indication and we have a key decision for that program in q4 a go no go decision to whether we proceed into phase three so that's where we are so again just to reiterate we we have an advanced vaccine platform self-amplifying mRNA that's approved in 32 countries and we're looking to that to help generate cash or or fuel for the value creating therapeutics pipeline franchise okay so let's start with um let's start with otc so you mentioned that there's going to be some data coming up um maybe kind of help us understand what what we're going to learn at that at that data readout i believe that's later later this year this this month this month okay um very good so um yeah

Miguel Nachamavitz Analyst — Citi

what are we going to learn? You know, what will you learn in terms of feedback from the FDA in terms of the path forward? And given you're studying both the pediatrics and the adults, you know, are there differences in terms of what you need to see there?

Speaker 2

Yeah. So we've had a pair or two type C meetings this year that we've, so we've engaged the regulatory agency to discuss the the path forward for this program and you're right that there's there's there's two general populations that we've segregated the otc deficiency community into you have stable adults and then you have pediatrics where there's the a larger commercial opportunity and higher unmet need with respect to pediatrics so as we've talked to them uh we've already indicated that both of these type c meetings were positive and productive but the details around the those meetings will be provided in more granularity at the at our communication later later this month so it's not just data that we'll be providing but it's also or the regulatory path forward and more granular feedback from those two type c meetings in terms of what data to expect you mentioned this is a phase two data set that includes europe and the us we have completed all our dosing and enrollment we've already communicated that so it's just about compiling the data and presenting it but why it's a unique data set is not only because it's additional data from our interim communications but it's in a format and additional data that was recommended through advice from the regulatory agency so from these type c meetings so we'll be able to communicate not just biomarker data but additional data that we had to go back retroactively and and and dig up uh and provide that uh for for wall street as well so it sounds like some of those details in terms of what biomarkers you're going to show are not you're not you're not ready not ready for prime time today that's something you'll tell me later or can you illuminate a little bit well we can we can discuss this a little bit the biomarkers for OTC divisions here are well-established. Ammonia is a bad actor. And that's always been a surrogate biomarker. It's something that you don't want ammonia, systemic ammonia. It crosses the blood brain barrier and does bad things. So we need to control that and show the regulatory agency that we can control ammonia. So ammonia is a key biomarker, but so is glutamine. And something that's helpful for uh people listening to the call today is that a lot of the patients that we're treating are already on ammonia scavengers and they're doing their best to control ammonia because that's you know that's what's very problematic so what they do is they take all these pills and they drink a lot of water and these pills are ammonia scavengers that sequester the ammonia and then they drink a lot of water and they urinate all the ammonia out and it's an exhaustive process, but that's how they're trying to manage ammonia. But what people don't realize is that these OTC patients, these subjects still do not feel well. Now, why is that if they're controlling their ammonia and doing their best? It's because of glutamine. So ammonia gets converted to glutamine in the body before it is scavenged. And so what we found and what the community well understands is that you have high levels of glutamine. Now, why is this a problem? Because glutamine crosses the blood-brain barrier as well, and it converts back to ammonia. So even if you're doing everything right, you can still have fog head, headaches, and just complications associated with the glutamine biomarker. So in addition to ammonia, which is a well-understood and surrogate biomarker there's glutamine and we're just finding uh um that these biomarkers are both of interest to not only the community but the regulatory agency uh we're and the other comment that i can provide is in stable adults there's an increased emphasis on glutamine because they've been managing at least to the best of their ability the ammonia levels already so they're more interested in getting that ammonia down so they feel better or the glutamine down so they can feel better. But in the pediatric population, there's elevated interest in ammonia because that's the population that is having severe disease and fatality occurs and severe hospitalization and hyper-anemic attacks and stuff like that in the children. So there's more of an emphasis on ammonia in the kids and an increased emphasis on glutamine in the adults.

Miguel Nachamavitz Analyst — Citi

Okay, that makes sense. so it sounds like there may be different metrics for the different populations uh for larger for the next set of studies um so we're going to get more direct longer longer duration of data those those uh those endpoints for those populations and then you're going to move into a phase three basically after you disclose this what's the what's the game plan there yeah in terms of In terms of the regulatory path forward, we're intentionally going to be communicating that with clarity, concurrent with the data readout later this month, so people don't have to wait very long.

Speaker 2

But that's one of the potential value inflections for this program, is not just the data, but providing what our proposed path forward is for pediatrics and adults.

Miguel Nachamavitz Analyst — Citi

Okay. By the way, I remember in a long time ago, there was another biomarker. Was it erotic acid or something like that? Did that one not feature heavily anymore?

Speaker 2

It's still there, but yes, that's right. There's erotic acid in urine. The urea cycle impacts a lot of biology. There's a lot of amino acids that are indirectly and directly impacted by this cycle that occurs in the liver, in the paraportal portion of the liver. So yes, erotic acid is a byproduct that can be measured. however it's it's quite variable so i don't know how helpful it can be supportive in nature but uh uh you know we're we're also looking at the n15 urea genesis yeah i wanted to ask about that too okay let's let's skip over to that so so tell us about that this is this uh i said i guess a radio labeled nitrogen yeah heavy nitrogen yeah we talked about multiple biomarkers already ammonia which is the bad actor glutamine which is also complicating and annoying people want to control and normalize that uh but this is a urea cycle disorder so you can track urea itself right uh and there's different ways to do so but there's a a relatively new assay this n15 assay that's very clever it's an academic um uh status right now but yes we have been collecting that data we consider that data to be supportive in nature um it's still an early technology so it's unlikely that it'll be um you know a validated primary endpoint or something like that but is it cool technology is it is it potentially supportive absolutely so we'll be collecting that data as well is that something the fda has heard of or understands or that's their sort of a learning mode there as far as it's so new combination of both do you want to comment on that yeah i yeah

Alan Cohen Other

Yeah, this is on. So this is Alan Cohen. Hi. So yeah, the enureagenesis cycle is really an exploratory endpoint. It's another way of validating, as Joe said, the fact that we're normalizing the urea cycle function. I think the things that the agency is going to be continuing to be interested in wanting to see are all the things that he just highlighted. The challenge is that when we only dose, we only give five doses in these patients over what is a relatively short period of time, 12 weeks. So being able to liberalize patients, urea binding medications, getting that dose down so that we can show that we've either stabilized it or normalized it is not something that's easy and feasible to do in such a short period of time. But what you would like to see is that it's stable. Patients are feeling better. They're reporting that they're not foggy. Perhaps they're gaining weight. Perhaps they're acting and they're liberalizing their protein intake. Even though we told these patients to remain on a stable diet, some of the things that we look forward to sharing in the near future are going to be those kinds of measures and those kinds of important observations. Okay.

Miguel Nachamavitz Analyst — Citi

All right. So we're looking forward to a lot. It sounds like there's going to be a very significant update then with a lot more detail. Yeah.

Speaker 2

And not just ARCT-810, but also the, and the regulatory feedback, but the platform in general, we're also going to use this as an opportunity to update folks on our intravenously dosed mRNA therapeutics platform for the liver. So it'll be a comprehensive update.

Miguel Nachamavitz Analyst — Citi

It's not going to be an average update. So stay tuned and I hope people... So there's something beyond the OTC in terms of another indication potentially?

Speaker 2

You have to tune in.

Miguel Nachamavitz Analyst — Citi

We'll wait.

Speaker 2

Okay.

Miguel Nachamavitz Analyst — Citi

All right. So maybe we could switch over talking about CF for a little bit. Yeah, another very important, another very important program. So maybe just first of all, just give us a snapshot of what you've shown, you know, you've done some dosing work, you had several updates last year. Just can I summarize where we are?

Speaker 2

Yeah, so lots happened in the CF program for Arcturus, but also within the CF community. Inhaled RNA therapeutics in general has been extraordinarily difficult for the field, whether it's antisense or siRNA, circular RNA, gene editing RNA, and mRNA, and everything in between. Humans just don't like to inhale lipids and rna that's just it's been a challenge for decades but we've now overcome that challenge through a lot of work over this past decade and a lot of investment from the cf foundation and other strategic partners but we're now in a place where we feel very good about the safety and tolerability profile we've we've completed 5 10 milligrams and 15 milligrams of daily dosing over 28 days and just to put a frame of reference on that that is much much much higher and much more consistent than any other program that's out there for uh so it's a it's a very differentiated profile and those differentiations of you know much more generous dosing of mRNA for a consistent period of time the reason we're able to do this is because of our next generation technology is differentiated. So we have a chemically different lipid nanoparticle that differentiates us from the field. We have a purification process for the RNA molecule itself that helps with safety and tolerability by removing these problematic impurities. These small RNA impurities can be very problematic for immune responses. And finally, our nebulization process, we took an off-the-shelf nebulizer and converted it and customized it to something that's more efficient at aerosolizing these types of therapeutics to prevent aggregates and macro particles and discombobulated particles, right? We need to retain the integrity of the particle, prevent aggregation, forming these macro particles that can be toxic as well. So if you combine that all together, a chemically different lipid nanoparticle that's biodegradable and non-accumulating, and then you have this more pure construct and optimized nebulizer, you pull that all together, you have a logarithmically different technology platform. and that's what we're seeing so far with respect to safety and tolerability and the reason I'm emphasizing that is that is what has plagued the entire field of inhaled RNA therapeutics has been safety and tolerability and thankfully we're we believe that we've addressed that challenge we're presently in a three-month study that started back in March and so we're deep into this open label study. We're not just evaluating this technology over 28 days, but now three months or 12 weeks of consecutive daily dosing. And we're in a position to share or provide a decision for this program in phase three. And now if it's okay, I'd like to discuss why we've guided a decision i'll just take a moment to do that so normally a ceo guides data or guides for completion of enrollment but we're guiding a decision to proceed now why is that it's because we signed a thermal fissure agreement uh in july and this is a very meaningful agreement for arcturus because if we if arcturus makes the decision to proceed into a phase three study then there this triggers up to a 40 million dollar contribution from thermo fisher to support our phase three budget that's a lot of money for a company of our size so the decision to proceed is what triggers it

Alan Cohen Other

so that's the guidance we're guiding this decision to proceed because it's associated with up to 40 million dollar uh commitment or contribution from thermal fisher to support our phase three budget for the cf program that's why we have that unique guidance in place maybe oh go ahead yeah so for some of your listeners and people in the room here that may not be as familiar with our program let me just give you some nuts and bolts so you'll at least know what's coming joe mentioned that we did dose ranging over four weeks at 5 10 and 15 milligrams when we did that early safety tolerability study it's certainly not long enough to give us a clinical signal of any meaning we did make an observation which we took forward selecting the 10 milligram, the middle dose, because we saw changes, improvements in radiographic findings in the lung. So that was the dose we took forward for the 12-week study. What we're dosing right now is upwards to 20 patients over a three-month period of time at 10 milligrams. We've gone outside of the United States to go into places like Turkey and Israel, which have a very high preponderance of people with no mutations or the kinds of patients that have the highest unmet medical need. And we're looking at not one, not two, but five potential endpoints that have clinical meaning. Two pulmonary function measures, including spirometry, looking at percent predicted FEV1, which is the most traditional endpoint that's been used for approvals for pulmonary diseases, including cystic fibrosis. Lung clearance index, which, by the way, the CF Foundation will be reporting out their natural history study, the REACH study, next month in October, and they're doing that study to help sponsors like us have a normative database for this adult population, two quality of life measures, and the radiographic high-resolution CT scanning data that we use to help select our dose for this phase two study. So at the end of this fourth quarter, or sometime during this fourth quarter, what Joe was mentioning is we're going to be reporting out, based on this open label study, what our intentions are with respect to moving the program forward and then we hope to share um substantive data sometime in the in the early part of next year okay um all right so a lot of a lot of kind of follow-ups on this uh important stuff so i guess first of all just can we just on the thermo arrangement just can you just clarify so that's what's the way that what's the structure there because it's not it doesn't sound like it's like it sounds like they're going to help fund this study but but is there a royalty?

Miguel Nachamavitz Analyst — Citi

Sure. It's not like, yeah, yeah.

Speaker 2

So this is a very unique agreement. It's one of a kind. There's never been a deal like this ever in the pharmaceutical industry. That's how unique this is. So there's more legal costs associating with putting this agreement because there's no template for it. But usually a CEO like myself wants to get money in the bank. That's what we're paid to do. And we do it by either selling stock or diluting the company, or we sell a royalty dilute the asset. This was neither. So the reason they're supporting this program is in exchange for a few years of commercial manufacturing exclusivity. So that's a unique deal. So no royalty, no equity, just a commercial manufacturing exclusivity. So why are they doing that for the CF program? Well, Arcturus, we haven't touched on it today, but we do have a product in 32 countries that's dosed five micrograms once a year. It's a COVID vaccine called Costave. That's five micrograms once a year. The CF program is 10,000 micrograms every day. So this is a significant commercial manufacturing contract. So large commercial manufacturers were approaching myself personally the company and building a relationship in order to close and get this commercial manufacturing exclusivity and what we ended up doing is this unique situation where a company of our size entering phase three we said hey how about if you support us with some contributions in phase three in exchange for commercial manufacturing exclusivity, and it worked. So it's a great relationship with Thermo Fisher. We're very pleased to be working with them with respect to our manufacturing strategy going forward, which is significant for the CF program.

Miguel Nachamavitz Analyst — Citi

Okay. So then sort of the intersecting question, Alan, you mentioned all the different, you know, the HRCT, high resolution CT, and then the lung clearance index, and then of course FEV1, which is the classic endpoint.

Speaker 2

So like, how do all these things intersect in terms of determining you know what's a good enough profile to trigger the decision to go into phase what do you what do you need to see there what do you want to see there everyone is very familiar with fev1 but perhaps the others are yeah obvious so i'd say two years ago uh there was several competitors uh with us in the inhaled uh therapeutic space for class 1cf And now, to a large extent, it feels like it's just us, especially with respect to transient mRNA, inhaled therapeutics. And the outlook is different. There is not a threshold like Wall Street, and trust me, I get it. Wall Street likes to see a number or a threshold that needs to be achieved in order to define success. But because we are first movers in this space, we are creating that threshold. That is the objective. what is success and that's what we're defining and we're not the first person to do this in cf a vertex was heroic a couple decades ago with orcambi it was the first modulator and they had to create the threshold and back then they only had fev lung function that is it it was two point something percent they did not have lung clearance index they did not have quality of life measures. They did not have high-res CT scan and AI tech and all this stuff. And they didn't have a REACH study, a normative natural history-like study from the CF Foundation to support it. They did it with just FEV. And so what they did was truly heroic. We don't need to do that, thankfully. We don't need to be heroic. We have FEV, we have LCI, multiple quality of life measures that are understood and validated to a large extent with the regulatory agencies. And then also we have a normative study to compare to and the high-res CT scan pictures before and after treatment that can all support this. So what we are in the business of doing is establishing what success looks like. So the follow-up question is like, well, what does success look like? Because you got to make a decision on something, right? And I don't want to to mislead people that were in the business of pushing some therapeutic forward if it isn't working. I know that Thermo Fisher may be supporting approximately half of the phase three budget, but Arcturus has to pay the other half. And we're not going to do this if it's not, if we don't deem it feasible or reasonable. But I want people here to understand the, I would say the immense and good pressure to get this over the finish line. The CF community, the class one CF community, they need a drug, they need to address this huge unmet need, very similar to what Vertex was experiencing a couple decades ago with Orkambi. And so it's kind of like resetting it, but this time we have a set of tools to help us establish what success looks like. And as a scientist, you know what success looks like. If the collective data is generally positive. I think it'll be easy to negotiate, convince, share, and get alignment with not just the CF community, the regulatory agency, the PIs involved, our partners, and of course, the senior management team and our board to know what success looks like. But that's the long answer to your question.

Alan Cohen Other

Let me just add one additional piece of color. I think over four weeks, simply safety and tolerability was really what we were looking for in dose selection. Twelve weeks, what we would like to see is some measure and indication that patients aren't just stable, but there's a modicum of improvement across at least one or more of the measures. So spirometry or lung clearance index or both. A phase three study would certainly need to be longer. And in many ways, these patients remind me of the idiopathic pulmonary fibrosis patient population, a different disease, of course, it's a restrictive lung disease. But when I was involved with getting profanidone and intendinib, both approved therapies through to the finish line and launch. What we were able to do there was show that we could stabilize and reduce the slope of the curve of reduction in lung function over time. And eventually that had implications on survival. I think in many ways, this is a population given that they really only get supportive care, that if we can just flatten the curve of decline, and they're averaging about one to two and a half percent of lung function loss annually. If we could stabilize those patients, I think that would be a huge step forward. And I think that's what Joe's referring to. So for purposes of the current study, we would certainly like to see across the five measures that we're looking at indications that we're not just stabilizing a subset of patients, but also that there are measures of improvement. And then for the longer term study for a phase three, I think stability as well as some measures of improvement would be what would be necessary to get a therapy like this approved for particularly the null population.

Miguel Nachamavitz Analyst — Citi

Which ones would be more likely to be in the gaining function versus stability amongst these endpoints? Is there an important area?

Alan Cohen Other

And I think the agency has consistently looked for functional measures, and right now I think among the five that we have, both pulmonary functions looking at mid-airways with spirometry, smaller airways with lung clearance index. And what's interesting about the high-resolution CT scan, which has never really been used as a primary endpoint for the agency across all sorts of diseases, including alpha-1 and others, although in my opinion it should be, there's demonstration in the literature that that could actually serve as a surrogate for stability or improvement in LCI, high-resolution CT scan changes. So we would certainly be having conversations with the agency talking about the value, the importance, and the translational literature that would support using lci not just in a supportive capacity so well sorry just clara how you getting you have hrct lci fev1 what are the other two and two quality of life matters so cfqrr and eq50 yeah these are and detailed surveys that are not just q a sessions these are you know validated surveys that are are respected and appreciated and considered meaningful right so And what the agency, as you know, granted, this is an open-label trial. So patients going in, particularly a group like this that has very little to offer, want to feel better. So an open-label study trying to ascertain whether or not the reported quality of life measures that we're getting back are genuine or, in fact, just people wanting to feel better. in a blinded study, which would certainly also be required for a phase three, we would be looking for demonstration of not just how a patient functions, but how they feel. So both of those actually carry enormous weight at the agency.

Miguel Nachamavitz Analyst — Citi

Okay, so you mentioned the REACH study, which I wanted to ask about. So right now, we're still waiting for the full data, is that right? Or do you guys know that data yet, and you already can start to make comparisons in terms of slopes?

Alan Cohen Other

We don't. So the CA Foundation, who we partner with, they provide us with our safety monitoring committee, for example. They've supported us financially in terms of our development. Joe mentioned earlier the aerosolization device. A lot of that work was paid for by the foundation. There's an October meeting in Atlanta where we understand that they will be sharing more data about the REACH study. My understanding is that it's largely, if not completely, enrolled. So that data should be made available in the near future. But it's not our data set. It's an independent data set.

Miguel Nachamavitz Analyst — Citi

I guess what I'm driving at is you want to see that data in the class ones and get the slopes and then sort of say like. And now we can compare our data sets. So that's going to be your normative comparison, right?

Alan Cohen Other

That would be correct. We would need to have access to that data or subsets of that data sufficiently so that we could power our phase three study.

Miguel Nachamavitz Analyst — Citi

But also make, I mean, also determine if it's a viable thing to do in the first place, right? I mean, obviously.

Speaker 2

You can appreciate there's degradation of the lung and lung function in these subjects over years, and hundreds of them are being evaluated in the study.

Miguel Nachamavitz Analyst — Citi

So if you had that, like, just hypothetically, if you had the REACH data today, you would be, you'd be able to make a decision.

Speaker 2

It increases the likelihood of success of the program. And it gives us more confidence on this decision that, that this is something we want to proceed with in phase three. And I just want to remind everyone that our preclinical efficacy data is really strong. We've shown that we were superior to positive controls and in a genetically engineered ferret model. And we already have seen in phase two, in a majority of subjects that received the 10 milligram dose, which is what we're utilizing now in 12 weeks, a majority of them, we've already seen improvements in, you know, mucus plug reduction in a majority of these people. So we've already seen some human indications of positive clinical signals. And then we have, you know, we've already seen some strong preclinical data. And the final reminder is, please always remember that the reason, the primary reason that all of these RNA companies have failed over decades has been safety and tolerability, not efficacy. It's because you just, in order to get this nest of disease dealt with, you need to pound it every day and resolve it. And that's really difficult to do, to reach a threshold of safety and tolerability that's reasonable enough to just keep hitting it every day until it resolves. Once it's resolved, then it opens up the opportunity for a lot of therapeutics because the lung will now be available for gene editing, for example. But it's our view that we need to resolve the disease in the nest with a daily treatment or at least a regularly dosed treatment.

Miguel Nachamavitz Analyst — Citi

Okay.

Alan Cohen Other

But since it's open label, this current 12-week study, you have some degree of insight into what's going on with these patients you have some flavor for the trend the direction of travel of things yes well it's been going since march and uh it's a 12-week study so you know i'll let people imply what that means from a safety and tolerability perspective but uh uh i mean you have you haven't reported any no adverse safety right no the we're still actively enrolling drug safety monitoring committee hasn't had any impact on our ability to continue to freely enroll patients And we announced and shared earlier this year that we, as I mentioned earlier, we went, in addition to the sites in the United States, which we expanded, we went into places like Turkey and Israel, where there is a very high preponderance of patients with null mutations to the tune of, it's about 5% to 10% in most typical centers in the United States.

Speaker 2

it's closer to 35 40 percent in places like jerky and israel so we're actively still enrolling the study and we will be able to report out as joe mentioned earlier our intentions and plans moving forward sometime in q4 yeah so so it's kind of going to be one when in q4 you'll have one update where it'll be you'll i assume you'll show us this this data or the only thing we're guiding in q4 the decision but it is an open label study so it's likely that the decision will happen before the study is complete and ready to share like the data like the data there's usually a time before you know the the the senior management team and the board will be confident in the data confident sufficiently confident to proceed prior to it being you know ready for communication now whether is it one day after the decision one week one quarter we haven't guided all we've got is is the decision, the go-no-go decision to be in Q4. And then shortly after that decision will be an opportunity to communicate the data.

Alan Cohen Other

Right. And I think there's been keen interest from yourself and others regarding real interest in wanting to see the data set and understanding what's been accomplished, what endpoints we've achieved, believable, important findings, which ones may have been less helpful, just like we would expect to see that from others, like the Vertex program, as joe alluded to earlier shut down earlier this year um you know we would hope to see some of that data in a reviewed setting there's no like intermediate case where you get us you know a good degree of confidence but you feel you need like like for example i mean you see this and you see something good and you see something trending nicely versus natural history but then you say okay maybe we'll maybe we need a little bit higher doses or not necessarily that but anything where

Miguel Nachamavitz Analyst — Citi

there's an intermediate case this is just a go no go black and white just a go no go we believe we've got the right dose and the right dosing regimen and and and the decision to play a role in the decision they just that's right they're just we negotiated that we'll have control of that decision they know that 40 million dollars is more to us than it is to them um so they trust that if we're proceeding that there's reason to do so right okay okay that makes sense um okay we're just about out of time but um wanted to ask very quickly yeah we're asking all the companies this just 30 seconds on the use of ai oh great in your company how do you yeah let me jump on that

Speaker 2

one very quickly so it it it's had a much more significant impact on our organization that i have imagined i'll just say that on every aspect of the of the company um it's it's really been impactful to a company at our stage with this type of platform. You can imagine that AI is used to design mRNA, designing antigens, help us with target selection, help us with impacting protein design, longer lasting proteins, more benign, less immunogenic proteins. We've been, there'll be an appropriate time for us to communicate our ai infrastructure uh but it's not today but uh we look forward to sharing some more details there later this year um that that could be very interesting but the short answer is yes it's been i would say very impactful and and uh very pleased to how the this the ai infrastructure development at arcturus and and its direct and meaningful impact on multiple programs okay i'll look forward to hearing more about that yeah and then of course the the data otc and then the decision on on cf so yeah thank you so much great great stuff Thanks for the time. Great talking to you.

Analyst Q&A · 1 question
Full-screen source Call document